Loading...
Market
Country first to report over 90% effectiveness of MVA-BN mpox vaccine by end of 2025?
2
Resolution / Starting Odds
United States • 25%
Germany • 25%
Brazil • 25%
India • 25%
Peer-reviewed scientific journals and WHO reports
Story
WHO Approves Bavarian Nordic's Mpox Vaccine for Adolescents Amid Global Concern
Oct 14, 2024, 08:15 AM
The World Health Organization (WHO) has approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the disease. This approval, announced on October 14, is expected to speed up the distribution of the vaccine globally. The WHO's decision comes amidst rising global concern about mpox, which has seen an increase in cases this year. In Kenya, the Ministry of Health has recorded 13 cases and one death. Health experts in El Paso, Texas, have also noted a rise in mpox cases compared to last year, recommending vaccination for those most at risk. The MVA-BN vaccine has shown 58% effectiveness in preventing mpox in the short term, while tecovirimat appears safe but its effectiveness remains unconfirmed.
View original story
Similar markets
Nigeria • 25%
Democratic Republic of Congo • 25%
Kenya • 25%
Other • 25%
United States • 25%
China • 25%
European Union • 25%
Other • 25%
Democratic Republic of the Congo • 25%
South Africa • 25%
Kenya • 25%
Uganda • 25%
1-5 • 25%
6-10 • 25%
11-15 • 25%
More than 15 • 25%
Yes • 50%
No • 50%
Nigeria • 25%
Kenya • 25%
South Africa • 25%
Other • 25%
Kenya • 25%
Nigeria • 25%
South Africa • 25%
Other • 25%
Less than 10 • 25%
10 to 20 • 25%
20 to 30 • 25%
More than 30 • 25%
Company A • 25%
Company B • 25%
Company C • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
UK • 14%
USA • 14%
Germany • 14%
France • 14%
Japan • 14%
Australia • 14%
Other • 14%